BZ371A represents a groundbreaking innovation in sexual health therapy. This synthetic non-hormonal peptide is derived from the venom of the Phoneutria nigriventer spider, known for causing powerful priapism in bite victims. BZ371A development journey began in 2014 through collaborative research with Brazilian universities, leading to an engineered peptide that maintains the beneficial properties of the original toxin while eliminating its harmful effects.
Revolutionary Mechanism of Action
Unlike conventional treatments, BZ371A works through a novel pathway by directly activating iNOS and nNOS enzymes, triggering Nitric Oxide production without requiring neurogenic stimulation. This cascade leads to cGMP synthesis, promoting soft muscle relaxation and increased blood flow even in the absence of sexual stimulation. This unique mechanism makes BZ371A particularly valuable for individuals whose neural pathways have been compromised, such as those who have undergone prostatectomy.
Advanced Topical Formulation
Formulated as a topical gel, BZ371A offers significant advantages over systemic treatments. Our clinical trials demonstrate excellent tolerability with minimal side effects due to its localized application. Unlike the original spider toxin, our engineered peptide doesn't interact with sodium channels, eliminating toxicity concerns while preserving therapeutic efficacy.
Addressing Unmet Medical Needs
BZ371A is currently advancing through clinical trials for both erectile dysfunction in men and sexual arousal disorder in women. It shows particular promise for post-prostatectomy patients and women with compromised vascular function in genital tissues. By restoring vascular homeostasis and physiological processes related to sexual arousal, BZ371A offers hope for millions seeking to reclaim their sexual health and intimacy.
Currently we are pursuing the development of BZ371A for the treatment of sexual dysfunction in both men and women, through independent but parell trials. The expected end of phase II for the women's is end of May 2025. The Phase II of clinical trials for men has been concluded in April 2025.
BZ371A, our novel topical peptide therapy, has demonstrated compelling efficacy in a Phase II clinical trial targeting erectile dysfunction in men recovering from radical prostatectomy. The study enrolled 74 participants across three arms: BZ371A alone, tadalafil alone, and a combination of both. Patients treated with BZ371A alone showed a 5× improvement in erectile function versus tadalafil. The most significant outcomes were observed in the combination arm, which achieved a 10× response rate compared to tadalafil alone, indicating a strong synergistic effect. Improvements were measured by the International Index of Erectile Function (IIEF-5), showing statistically and clinically meaningful gains. Importantly, BZ371A was well-tolerated, with no serious adverse events reported. These results highlight BZ371A’s potential to address a major unmet need for patients with nerve damage following prostate surgery, offering a new mechanism of action independent of neural signaling.
Read the full press release for full details and methodology.This innovative topical peptide therapy is designed to address the unique challenges faced by these patients, offering a new approach to preserve and restore erectile function where existing treatments fall short. We remain committed to advancing solutions that bring renewed hope and quality of life to men and couples affected by post-surgical erectile dysfunction.